Protagonist Therapeutics Price to Sales Ratio 2015-2022 | PTGX

Historical PS ratio values for Protagonist Therapeutics (PTGX) over the last 10 years. The current P/S ratio for Protagonist Therapeutics as of July 01, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Protagonist Therapeutics P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-07-01 7.86 8.03
2022-03-31 23.68 $0.98 24.20
2021-12-31 34.20 $0.59 57.89
2021-09-30 17.72 $0.57 31.14
2021-06-30 44.88 $0.71 63.62
2021-03-31 25.90 $0.84 30.67
2020-12-31 20.16 $0.84 24.11
2020-09-30 19.55 $0.78 25.16
2020-06-30 17.66 $0.58 30.46
2020-03-31 7.06 $0.06 121.25
2019-12-31 7.05 $-0.01 0.00
2019-09-30 12.01 $-0.01 0.00
2019-06-30 12.11 $0.10 116.05
2019-03-31 12.57 $0.99 12.74
2018-12-31 6.73 $1.43 4.70
2018-09-30 10.29 $1.97 5.23
2018-06-30 6.72 $2.22 3.03
2018-03-31 8.59 $1.67 5.15
2017-12-31 20.80 $1.16 17.98
2017-09-30 17.67 $0.52 34.03
2017-06-30 11.31 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.382B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00